When EBITDA Doesn’t Tell the Story: Valuing Deep-Tech IP

Some of the most valuable companies we see in photonics and other deep-tech fields are also the hardest to sell. They have decades of research behind them, a deep patent portfolio, and products that perform at the edge of what physics allows. Yet their EBITDA is thin, sometimes close to zero.

That mismatch creates a problem for both sides of a deal. Buyers trained to pay a multiple of earnings see little to multiply. Founders who know what it would cost to rebuild their technology feel undervalued, sometimes insulted. Too often the result is no deal at all, or a deal priced as if the IP did not exist.

The problem is not unique to photonics. It shows up in medical devices, advanced materials, space hardware and scientific instruments: any business where the asset is the know-how, and the income statement has not caught up.

Why buyers struggle

Most middle-market buyers start with a multiple of adjusted EBITDA. That works for a distributor or a contract manufacturer, where earnings track the value of the business closely. It breaks down for an IP-heavy company for four reasons.

• Earnings understate the asset. Much of the R&D was funded by government contracts or grants, so it never ran through the income statement as an investment. A buyer looking at EBITDA sees the residue, not the asset.
• Revenue is lumpy. Program-based and contract revenue rises and falls with awards, which makes any single year a poor baseline for a multiple.
• The value sits in a few heads. Buyers worry, rightly, about what happens if the founders or lead scientists walk out after closing.
• The upside is a forecast. New products the technology makes possible are real but unproven, and buyers discount what they cannot see in a CIM.

None of these objections is unreasonable. The mistake is letting them set the price by default.

Valuation lenses that work

The answer is not to ignore earnings. It is to put other measures beside them, so the conversation is about what the business is worth to a particular buyer, not what one line of the income statement says.

1. Replacement cost. What would it take a buyer to build this capability itself: the engineering years, the facilities, the failed experiments and the time to market? For a strategic buyer, the time saved is often worth more than the dollars, especially in a market moving as fast as AI-driven optics or alternatives to GPS.
2. Strategic synergy value. A buyer that can put the technology into its existing products, channels and customer base can earn far more from it than the company does standalone. The seller’s job is to make those synergies concrete enough that the buyer pays for part of them.
3. Relief from royalty. Valuers often price patents by asking what the buyer would pay to license them instead of owning them. It translates a patent portfolio into an income stream a finance team recognizes.
4. Option value of the pipeline. Products in development, new applications and adjacent markets are options on future growth. Each one can be framed with its own market, timeline and probability, rather than buried in a single hockey-stick forecast.

Used together, these give a buyer a way to justify a price that a trailing-EBITDA multiple never would. They also give the seller a defensible answer when a buyer says, “we don’t pay for IP.”

Process matters as much as the numbers

A standard sale process sends a confidential information memorandum to a list of buyers and asks for indications of interest by a deadline. For a business valued on its earnings, that works well. For an IP-rich company, it often fails, because buyers are being asked to put a number on technology they have only read about.

In our experience, the better approach puts management meetings ahead of price indications. Buyers spend time with the founders and engineers, see the lab, and test the technology against their own roadmap. Only then are they asked for a valuation. The buyers who engage this way come back with a view of what the technology is worth to them, not a discounted multiple of last year’s results.

Two other process choices matter:

• Pick buyers for fit, not volume. The right strategic buyer may be a test and measurement company, a defense prime or a component maker integrating up the value chain. A pure financial buyer underwriting the business standalone will usually value it on earnings.
• Protect the crown jewels. When likely buyers are also competitors, staged disclosure and clean-team arrangements let the seller show enough to support value without handing over its trade secrets before a deal is signed.

What owners should do now

The owners who get full value for their technology prepare well before they go to market. A year or two of groundwork can change the outcome.

• Document the R&D investment. Total up what has gone into the technology, from all sources, including government funding. It is the starting point for a replacement-cost argument.
• Clean up the IP. Make sure patents are assigned to the company, maintained and mapped to the products they protect. Know when the key families expire and what protects the business after that.
• Tie the technology to markets. For each application, size the market and name the buyers who would care. Buyers pay for synergies they can see.
• Reduce key-person risk. Build a second layer of technical leadership and put retention and IP agreements in place before a buyer asks.
• Get the numbers right. Thin EBITDA is a manageable story; inconsistent EBITDA is not. Have adjustments reviewed before materials go out.
• Clean up investor agreements. Strategic investors from earlier rounds may hold information rights, board observer seats or notice rights. Understand them before a sale process starts.

When EBITDA does not tell the story, the seller has to tell it, with evidence and through the right process. If you own a technology-driven business and are thinking about what comes next, we would welcome a conversation.